# Agile Therapeutics Inc. (AGRX)

Source: https://www.quantisnow.com/company/AGRX
Generated: 2026-11-03T07:08:23.898Z

- Ticker: AGRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: agiletherapeutics.com

## About

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

## Latest AGRX news and filings

- 2024-08-28 12:02 UTC [SEC Form RW filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-agile-therapeutics-inc-5674352)
- 2024-08-28 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-agile-therapeutics-inc-5674085)
- 2024-08-28 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-agile-therapeutics-inc-5674078)
- 2024-08-28 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-agile-therapeutics-inc-5674072)
- 2024-08-26 21:45 UTC [SEC Form 4] [Chief Administrative Officer Gilmore Geoffrey returned $30,789 worth of shares to the company (20,256 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-administrative-officer-gilmore-geoffrey-returned-30789-worth-of-shares-5672319)
- 2024-08-26 21:42 UTC [SEC Form 4] [Chief Financial Officer Coiante Scott M returned $30,522 worth of shares to the company (20,080 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-coiante-scott-m-returned-30522-worth-of-5672317)
- 2024-08-26 21:41 UTC [SEC Form 4] [Chief Supply Chain Officer Conway Robert G returned $20,564 worth of shares to the company (13,529 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-supply-chain-officer-conway-robert-g-returned-20564-worth-5672315)
- 2024-08-26 21:40 UTC [SEC Form 4] [Chief Medical Officer Korner Paul returned $20,520 worth of shares to the company (13,500 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-korner-paul-returned-20520-worth-of-shares-5672312)
- 2024-08-26 21:39 UTC [SEC Form 4] [Chief Commercial Officer Welsh Amy returned $20,520 worth of shares to the company (13,500 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-welsh-amy-returned-20520-worth-of-shares-5672307)
- 2024-08-26 21:37 UTC [SEC Form 4] [Director Torrente Josephine returned $1,500 worth of shares to the company (987 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-torrente-josephine-returned-1500-worth-of-shares-to-the-5672305)
- 2024-08-26 21:35 UTC [SEC Form 4] [Director Barbari Sharon returned $1,479 worth of shares to the company (973 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-barbari-sharon-returned-1479-worth-of-shares-to-the-5672301)
- 2024-08-26 21:34 UTC [SEC Form 4] [Director Carson Sandra returned $1,479 worth of shares to the company (973 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-carson-sandra-returned-1479-worth-of-shares-to-the-5672300)
- 2024-08-26 21:33 UTC [SEC Form 4] [Chief Executive Officer Altomari Alfred returned $72,578 worth of shares to the company (47,749 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-altomari-alfred-returned-72578-worth-of-shares-5672299)
- 2024-08-26 21:32 UTC [SEC Form 4] [Director Fischer Seth H. Z. returned $1,484 worth of shares to the company (976 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-fischer-seth-h-z-returned-1484-worth-of-shares-5672298)
- 2024-08-26 21:30 UTC [SEC Form 4] [Director Hubbard John W returned $1,484 worth of shares to the company (976 units at $1.52), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-hubbard-john-w-returned-1484-worth-of-shares-to-5672295)
- 2024-08-26 21:27 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-agile-therapeutics-inc-5672280)
- 2024-08-26 21:27 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-agile-therapeutics-inc-5672279)
- 2024-08-26 21:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-agile-therapeutics-inc-5672276)
- 2024-08-26 21:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-agile-therapeutics-inc-5672275)
- 2024-08-26 21:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-agile-therapeutics-inc-5672274)
- 2024-08-26 21:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-agile-therapeutics-inc-5672273)
- 2024-08-26 21:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-agile-therapeutics-inc-5672272)
- 2024-08-26 21:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-agile-therapeutics-inc-5672270)
- 2024-08-26 21:20 UTC [SEC Form POS AM filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-agile-therapeutics-inc-5672255)
- 2024-08-26 21:17 UTC [SEC Form POS AM filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-agile-therapeutics-inc-5672244)
- 2024-08-26 21:16 UTC [SEC Form POS AM filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-agile-therapeutics-inc-5672234)
- 2024-08-26 21:11 UTC [SEC Form 8-K] [Agile Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events](https://www.quantisnow.com/insight/agile-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-5672212)
- 2024-08-26 21:05 UTC [Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.](https://www.quantisnow.com/insight/agile-therapeutics-inc-announces-completion-of-acquisition-by-insud-pharma-5672186)
- 2024-08-12 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-agile-therapeutics-inc-5655129)
- 2024-07-25 10:06 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-agile-therapeutics-inc-5626536)
- 2024-07-22 20:50 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-agile-therapeutics-inc-5620532)
- 2024-07-16 20:21 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-agile-therapeutics-inc-5611001)
- 2024-07-16 20:15 UTC [SEC Form 8-K] [Amendment: Agile Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-agile-therapeutics-inc-filed-sec-form-8-k-financial-statements-5610946)
- 2024-07-15 20:35 UTC [SEC Form 8-K] [Amendment: Agile Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-agile-therapeutics-inc-filed-sec-form-8-k-financial-statements-5608708)
- 2024-07-12 21:29 UTC [SEC Form PREM14A filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-prem14a-filed-by-agile-therapeutics-inc-5606817)
- 2024-07-09 18:20 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-agile-therapeutics-inc-5599648)
- 2024-07-02 19:44 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-agile-therapeutics-inc-5589660)
- 2024-06-27 20:31 UTC [SEC Form RW filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-agile-therapeutics-inc-5581628)
- 2024-06-26 12:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Agile Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-agile-therapeutics-inc-5577741)
- 2024-06-26 12:00 UTC [SEC Form 8-K] [Agile Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/agile-therapeutics-inc-filed-sec-form-8-k-entry-into-a-5577655)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AGRX
- Earnings history: https://www.quantisnow.com/earnings/AGRX
- Dividend history: https://www.quantisnow.com/dividends/AGRX
- Insider transactions: https://www.quantisnow.com/insiders/AGRX
- Options chain: https://www.quantisnow.com/options/AGRX
- SEC 8-K filings only: https://www.quantisnow.com/company/AGRX/8-k
- RSS and alerts for AGRX: https://www.quantisnow.com/docs/rss-feeds.md